4 completed, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow EC20: new trials by email Literature Review of EC20 trials Research Report on EC20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery EC1456, 99mTc-Etarfolatide - Ovary Cancer | Phase 1 | Completed | Endocyte | 3 | 2017-01-24 | 2019-02-07 |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) EC145, Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®), placebo - Ovarian Cancer | Phase 3 | Terminated | Endocyte | 441 | 2011-04-22 | 2021-09-30 |
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Endocyte | 203 | 2011-03-01 | 2021-04-01 |
| Study of EC0489 for the Treatment of Refractory or Metastatic Tumors EC0489, Injection, EC20 - Cancer | Phase 1 | Completed | Endocyte | 65 | 2009-04-01 | 2012-08-08 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer | Phase 2 | Completed | Endocyte | 162 | 2008-09-01 | 2015-01-07 |
Neoplasms (3) · Ovarian Neoplasms (3) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Endocyte (5)
United States (2) · Canada (1)
Alison Armour, MB ChB, BSc, MSc, MD, MRCP (1) · Binh Nguyen, MD (1) · Binh Nguyen, MD, PhD (1) · Richard A Messmann, MD, MHS, MSc (1)